Enpatoran is under clinical development by Merck and currently in Phase II for Coronavirus Disease 2019 (COVID-19) Pneumonia.
MIL-62 is under clinical development by Beijing Mabworks Biotech and currently in Phase II for Splenic Marginal Zone B-Cell Lymphoma.
Long-Acting Injectable Program is under clinical development by Intra-Cellular Therapies and currently in Phase I for Schizoaffective Disorder.
CSL -889 is under development for the treatment of acute vascular occlusive crisis (VOC) in sickle cell disease. The drug candidate consists of plasma-derived hemopexin. It is administered through ...
BI-765049 is under clinical development by Boehringer Ingelheim International and currently in Phase I for Non-Small Cell Lung Cancer.
Amesanar is under clinical development by RHEACELL and currently in Phase II for Diabetic Foot Ulcers. According to GlobalData, Phase II drugs for Diabetic Foot Ulcers does not have sufficient ...
(Nivolumab + relatlimab) is under clinical development by Bristol-Myers Squibb and currently in Phase III for Non-Small Cell Lung Cancer.
BARS-13 is under clinical development by Beijing Advaccine Biotechnology and currently in Phase II for Respiratory Syncytial Virus (RSV) Infections.
H-1337 is under clinical development by D. Western Therapeutics Institute and currently in Phase II for Open-Angle Glaucoma.
AT-19 is under clinical development by Shanghai YaKe Biotechnology and currently in Phase II for Primary Mediastinal B-Cell Lymphoma.
ANP-390 is under clinical development by AlphaNavi Pharma and currently in Phase I for Peripheral Neuropathic Pain.
NUC-7738 is under clinical development by NuCana and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...